PDL BioPharma, Inc. (PDLI)
-NasdaqGS | Prev Close: | 8.26 |
|---|
| Open: | N/A |
|---|
| Bid: | 8.10 x 2600 |
|---|
| Ask: | 8.26 x 100 |
|---|
| 1y Target Est: | 6.90 |
|---|
| Beta: | 0.51 |
|---|
| Next Earnings Date: | 2-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 6.18 - 8.48 |
|---|
| Volume: | 1,500 |
|---|
| Avg Vol (3m): | 1,781,540 |
|---|
| Market Cap: | 1.16B |
|---|
| P/E (ttm): | 5.46 |
|---|
| EPS (ttm): | 1.51 |
|---|
| Div & Yield: | 0.60 (7.30%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- PDL BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote ofEDGAR Online(Wed, May 22)
- July Options Now Available For PDL BioPharmaat Forbes(Mon, May 20)
- PDL BIOPHARMA, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Jim Cramer: Buy Google, First Solar, Marathon Petroleum, and These 2 Stocksat Wall St. Cheat Sheet(Thu, May 16)
- 2 Scariest Dividend Stocks in Health Careat Motley Fool(Thu, May 16)
- Cramer's Lightning Round - SunPower Has Staying Power (5/15/13)at Seeking Alpha(Thu, May 16)
- 'Mad Money' Lightning Round: Ford Is a Buyat TheStreet(Thu, May 16)
- Lightning Round: Berkshire Hathaway, Ford & Moreat CNBC(Wed, May 15)
- Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companiesat Motley Fool(Wed, May 15)
- Lightning Round: AOL, Pinnacle Foods & Moreat CNBC(Tue, May 14)
- Here Is A Portfolio Model That Worksat Seeking Alpha(Tue, May 14)
- Investors are Digesting These Healthcare Stock Earnings Insightsat Wall St. Cheat Sheet(Sun, May 12)
- 4 Buy-Rated Dividend Stocks: COP, ETE, PDLI, TEGat TheStreet(Fri, May 10)
- PDL BioPharma CEO Discuses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- PDL BioPharma Earnings: Here’s Why Shares are Up Nowat Wall St. Cheat Sheet(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | 4.26 |
|---|
| P/S (ttm): | 2.97 |
|---|
| Ex-Dividend Date: | 03-Dec-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.64 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.54 |
|---|
| Mean Recommendation*: | 3.2 |
|---|
| PEG Ratio (5 yr expected): | 0.36 |
|---|
Business Summary
PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targ...
View More